Lupin gets CDSCO Panel nod for Rifapentine Dispersible Tablet 150 mg Dr. Divya Colin19 Dec 2023 2:06 PMNew Delhi: Granting the local clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Investigational Three-Month TB Regimen Safe but Ineffective Dr. Kamal Kant Kohli7 July 2023 4:00 AMThe first clinical trial of three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavourable outcomes with...
Single-dose rifapentine may prevent leprosy spread in household contacts: NEJM Medha Baranwal19 May 2023 4:30 AMChina: A trial has shown that single-dose rifapentine lowers the incidence of leprosy among household contacts over four years compared with no...
Lupin, Global Agencies collaborate to support tuberculosis prevention treatment Ruchika Sharma7 Oct 2022 9:00 AMMumbai: Global pharma major, Lupin Limited has announced that it has reached an agreement with Unitaid, The Aurum Institute, the Clinton Health Access...
Lupin gets CDSCO panel okay to manufacture, market tuberculosis drug Rifapentine Dr. Divya Colin5 March 2022 12:05 PMNew Delhi: Drug major, Lupin has got a go-head from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organization to (CDSCO)...
New tuberculosis regimen shortens treatment to four months: Study Hina Zahid16 Jun 2021 3:30 AMShortening the treatment time improves adherence, decreases costs to programs and decreases the burdens on patients themselves.USA: A 4-month...
Four-month rifapentine regimen for TB equally effective as 6-month standard regimen: NEJM Medha Baranwal6 May 2021 1:15 AMUSA: The effectiveness of a 4-month rifapentine-based regimen containing moxifloxacin is noninferior to the standard 6-month regimen for the treatment...
Shorter TB treatment regimen as effective as longer course: CDC Study Medha Baranwal23 Oct 2020 1:43 PMUSA: A four-month daily treatment containing high-dose rifapentine with moxifloxacin is as effective as the currently recommended six-month daily...
